Scrip | What Does 2023 Hold for Biopharma?
Jan 2023
Originally posted by Scrip on January 9, 2023.
Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for biopharma mergers and acquisitions (M&A) trends in 2023.
Summary
-
Tony Crisman, Managing Director in Lincoln International’s Healthcare Group, reveals several anticipated 2023 biopharma mergers and acquisitions trends with Scrip.
- Sign up to receive Lincoln's perspectives
Contributor
Meet Professionals with Complementary Expertise
I enjoy working closely with clients to overcome challenging situations and to develop strategies to meet their business goals.
Dirk-Oliver Löffler
Managing Director | Management Board Member
Frankfurt
Related Perspectives
Real Deals | Healthcare M&A Resilience
What trends have you seen in the last quarter in relation to valuations in the healthcare space? Matthew Lee: It’s early days to get an accurate read on valuations as… Read More
Lincoln International Announces Strategic Partnership with Australian Corporate Advisory Firm, Miles Advisory Partners
Lincoln International, a global investment banking advisory firm, announced today that it has established a strategic partnership with Miles Advisory Partners, an Australian-based independent corporate advisory firm, servicing the robust… Read More
Lincoln International’s Global Healthcare Group Announces Strong Results in 2022
Lincoln International’s global Healthcare Group enjoyed another consecutive year of record-setting mergers and acquisitions (M&A) deal volume, average deal size and a record backlog heading in to 2023. Our performance… Read More
Scrip | What Does 2023 Hold for Biopharma? Part 6: Artificial Intelligence
Originally posted by Scrip on February 10, 2023. Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for artificial intelligence in the biopharma industry. View the original article.
